How does susceptibility prevalence impact on the performance of disk diffusion susceptibility testing?

Diagnostic Microbiology and Infectious Disease

Volumn 49, Issue 2, 2004, Pages 131-139

  Lamy, Brigitte ^a,b   Carret, Gerard ^a,b   Flandrois, Jean Pierre ^a,b   Delignette Muller, Marie Laure ^c  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

^c VETAGRO SUP   (France)

Author keywords

Antimicrobial susceptibility testing; Simulation; Susceptibility prevalence; Test performance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; LOMEFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; EXPERIMENTAL MODEL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERFORMANCE; PREVALENCE; PRIORITY JOURNAL; SIMULATION;

AGAR; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; PREDICTIVE VALUE OF TESTS;

EID: 2942525270     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2004.01.003     Document Type: Article

References (24)

1. Acar JF, Goldstein FW (1997). Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 24, S67-73
2. Barrett S.P., Savage M.A., Rebec M.P., Guyot A., Andrews N., Shrimpton S.B. Antibiotic sensitivity of bacteria associated with community-acquired urinary tract infection in Britain. J Antimicrob Chemother. 44:1999;359-365
3. Burns J.L., Saiman L., Whittier S., Larone D., Krzewinski J., Liu Z., Marshall S.A., Jones R.N. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol. 38:2000;1818-1822
4. Cormican M.G., Erwin M.S., Jones R.N. Multi-center validation of proposed disk diffusion susceptibility testing interpretive criteria for lomefloxacin using more than 1, 500 clinical isolates. Diagn Microbiol Infect Dis. 24:1996;169-172
5. Craig B.A. Modeling approach to diameter breakpoint determination. Diagn Microbiol Infect Dis. 36:2000;193-202
6. Daza R., Gutierrez J., Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents. 18:2001;211-225
7. Efron B. Bootstrap methods Another look at the jackknife. Ann Stat. 7:1979;1-26
8. Elder BL, Hansen SA, Kellogg JA, Marsik FJ, Zabransky RJ (1997). Verification and validation of procedures in the clinical microbiology laboratory. Coordinating ed, BW McCurdy. Washington, D.C.: American Society for Microbiology, pp 7-8
9. th July 2003
10. Farrell D.J., Morrissey I., de Rubeis D., Robbins M., Felmingham D. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J Infect. 46:2003;94-100
11. Ferraro M.J. Should we reevaluate antibiotic breakpoints? Clin Infect Dis. 33:2001;S227-S229
12. Fletcher R, Fletcher S, Wagner E (1996). Clinical epidemiology. The essentials. Baltimore, USA: Williams and Wilkins
13. Fuchs P.C., Barry A.L., Thornsberry C., Gavan T.L., Jones R.N. In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing Regression analysis, tentative interpretive criteria, and quality control limits. Antimicrob Agents Chemother. 24:1983;31-38
14. Glupczynski Y., Delmee M., Goossens H., Struelens M. Distribution and prevalence of antimicrobial resistance among gram-negative isolates in intensive care units (ICU) in Belgian hospitals between 1996 and 1999. Acta Clin Belg. 56:2001;297-306
15. Gruneberg R.N. Changes in urinary pathogens and their antibiotic sensitivities, 1971-1992. J Antimicrob Chemother. 33:1994;1-8
16. Howard A.J., Magee J.T., Fitzgerald K.A., Dunstan F.D. Factors associated with antibiotic resistance in coliform organisms from community urinary tract infection in Wales. J Antimicrob Chemother. 47:2001;305-313
17. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections the ECO.SENS Project. J Antimicrob Chemother. 51:2003;69-76
18. MacGowan A.P., Brown N.M., Holt H.A., Lovering A.M., McCulloch S.Y., Reeves D.S. An eight-year survey of the antimicrobial susceptibility patterns of 85, 971 bacteria isolated from patients in a district general hospital and the local community. J Antimicrob Chemother. 31:1993;543-557
19. Medeiros A.A., Crellin J. Evaluation of the Sirscan automated zone reader in a clinical microbiology laboratory. J Clin Microbiol. 38:2000;1688-1693
20. Mouton J.W. Breakpoints Current practice and future perspectives. Int J Antimicrob Agents. 19:2002;323-331
21. National Committee for Clinical Laboratory Standards (NCCLS) (2002). Performance standards for antimicrobial susceptibility testing; Twelfth informational supplement. NCCLS document M100-S12. Pa, USA: NCCLS
22. Phillips I. Reevaluation of antibiotic breakpoints. Clin Infect Dis. 33:2001;S230-S232
23. Robert J., Cambau E., Grenet K., Trystram D., Péan Y., Fievet M.H., Jarlier V. Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital 1992-1998. Clin Microbiol Infect. 7:2001;553-561
24. Schito G.C. Is antimicrobial resistance also subject to globalization? Clin Microbiol Infect. 8:2002;1-8